Temple University Health System’s preparations for and treatment of patients amidst the coronavirus pandemic continue to be part of the media’s COVID-19 coverage.
- Tony S. Reed, MD, PhD, MBA, Executive Vice President and Chief Medical Officer of Temple University Health System, spoke with the Philadelphia Inquirer about what hospitals, health systems and the public can do now to better prepare for the next potential COVID-19 wave as the Omicron surge begins its decline.
- Thomas Fekete, MD, MACP, Thomas Durant Chair and Professor of Medicine and Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University, participated in a Q&A video interview with the College of Physicians of Philadelphia. Dr. Fekete discussed a variety of COVID-19-related topics, including masking, testing, vaccination, new therapies, the experience at Temple during the pandemic, and transitioning to an endemic version of the virus.
- Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, Clinical Professor and Director of the Postgraduate Year Two Infectious Diseases Residency at the Temple University School of Pharmacy and Clinical Pharmacist Specialist in Infectious Diseases at Temple University Hospital, provided perspective to Healio’s Infectious Disease News about the U.S. Food and Drug Administration (FDA)’s recent decision to halt the use of two monoclonal antibody treatments for COVID-19 after they were shown to be ineffective against the Omicron variant.
- David Becker, MD, FACC, Director of the Preventive and Integrative Heart Health Program at the Temple Heart and Vascular Institute, wrote a blog post for the Philadelphia Inquirer about Pfizer’s Paxlovid, an antiviral pill for COVID-19. Dr. Becker addressed concerns about Paxlovid, namely interactions with other widely used medications.